Annovis Bio, Inc. (ANVS) Stock Score, Valuation & Financial Research

Annovis Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANVS

Annovis Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.27. These figures are a research snapshot, not a buy or sell recommendation.

What Annovis Bio, Inc. does

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Annovis Bio is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings to fund the research, development, and clinical trial costs associated with its pipeline of investigational drug candidates for neurodegenerative diseases.

Products and services

  • The company is developing buntanetap for Alzheimer's and Parkinson's disease, as well as ANVS405 for traumatic brain injury and stroke, and ANVS301 for cognitive enhancement.

Brands and product families

  • Buntanetap — Lead investigational oral therapy candidate for Alzheimer's and Parkinson's disease. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs to manage and conduct its clinical trials. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party manufacturers for the production of its drug candidates. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for Alzheimer's, Parkinson's, and other neurodegenerative conditions. Source

Business strengths to evaluate

  • Intellectual property portfolio including 40 granted patents Source

Business risks and research considerations

  • Substantial doubt regarding ability to continue as a going concern Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source

Sources: Company research source · Intellectual property portfolio including 40 granted patents

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANVS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.27
Market capitalization:
54.03M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -49.52M
Free cash flow:
USD -25.62M
Cash:
USD 18.73M
Total debt:
USD 0.00
EPS:
USD -1.79

What stands out

  • Free cash flow is USD -25.62M, negative for the stored period.
  • The balance sheet shows USD 18.73M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 18.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANVS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANVS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANVS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANVS to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ANVS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ANVS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.